ALT - Altimmune, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
2.2800
+0.0300 (+1.33%)
As of 11:59AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close2.2500
Open2.2000
Bid2.2500 x 1300
Ask2.2700 x 1000
Day's Range2.2000 - 2.2900
52 Week Range1.7000 - 36.2500
Volume55,905
Avg. Volume266,865
Market Cap34.971M
Beta (3Y Monthly)2.17
PE Ratio (TTM)N/A
EPS (TTM)-4.1610
Earnings DateNov 11, 2019 - Nov 15, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date2017-01-20
1y Target Est8.60
Trade prices are not sourced from all markets
  • GlobeNewswire

    Altimmune Appoints M. Scott Harris, M.D. as Chief Medical Officer

    Altimmune, Inc. (ALT), a clinical-stage biopharmaceutical company, today announced it has appointed M. Scott Harris, M.D. as Chief Medical Officer. Dr. Harris is succeeding Dr. Sybil Tasker, who resigned June 30, 2019 to continue her professional focus on infectious diseases. “Dr. Harris is a seasoned medical professional with extensive experience in hepatology and gastroenterology and broad expertise in managing clinical trials from early stage development through successful Phase 3 trials.

  • GlobeNewswire

    Altimmune Announces $3.7 Million in Additional BARDA Funding to Advance NasoShield™ Clinical Development

    Altimmune, Inc. (ALT), a clinical-stage biopharmaceutical company, today announced that the Biomedical Advanced Research and Development Authority (BARDA) is modifying its existing anthrax vaccine development contract with Altimmune by awarding an additional $3.7 million. The increase in funding is primarily directed toward a Phase 1b clinical trial of NasoShield to evaluate alternative methods of intranasal dosing in humans. In 2018, BARDA awarded Altimmune $2.5 million for further NasoShield development including a comparison of different methods of administration of the vaccine in preclinical models.

  • GlobeNewswire

    Altimmune Announces Second Quarter 2019 Financial Results and Provides a Business Update

    GAITHERSBURG, Md., Aug. 13, 2019 -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the three and six months.

  • Germantown biopharma regains compliance with Nasdaq
    American City Business Journals

    Germantown biopharma regains compliance with Nasdaq

    The Nasdaq Hearings Panel concluded Neuralstem showed compliance by meeting the minimum $1 bid price requirement.

  • GlobeNewswire

    Altimmune to Announce Second Quarter 2019 Financial Results on August 14

    GAITHERSBURG, Md., Aug. 05, 2019 -- Altimmune, Inc. (Nasdaq: ALT), a clinical stage biopharmaceutical company focused on developing liver disease and immune modulating.

  • GlobeNewswire

    Altimmune Announces Closing of Acquisition of Spitfire Pharma, Inc.

    Altimmune, Inc. (ALT), a clinical-stage biopharmaceutical company, today announced the closing of the previously announced acquisition of Spitfire Pharma, Inc., including the product candidate ALT-801, a potent GLP-1/Glucagon receptor co-agonist for the treatment of non-alcoholic steatohepatitis (NASH). The number of shares to be issued was determined based on the average of the closing prices of the Company’s common stock as reported on the Nasdaq Global Market for the twenty consecutive trading days prior to and including July 8, 2019, the date the definitive agreement was signed. Altimmune is a clinical stage biopharmaceutical company focused on developing liver disease and immune modulating therapies.

  • Not just a vaccine company: How this Gaithersburg biotech CEO plans to grow the business
    American City Business Journals

    Not just a vaccine company: How this Gaithersburg biotech CEO plans to grow the business

    The Gaitherburg biotech’s CEO, not yet a year into his tenure, sees the prospect of more acquisitions or licensing deals going forward.

  • Altimmune to acquire California company for up to $93M
    American City Business Journals

    Altimmune to acquire California company for up to $93M

    The deal puts Spitfire’s flagship product candidate — a treatment for nonalcoholic steatohepatitis, or NASH — into Altimmune’s pipeline of flu and anthrax vaccines.

  • Germantown stem cell therapy company proposes $7M offering amid delisting threat
    American City Business Journals

    Germantown stem cell therapy company proposes $7M offering amid delisting threat

    The company’s future on the Nasdaq hangs in the balance, as its share price continues to sit below a buck in the wake of a delisting threat from the exchange.

  • Benzinga

    Altimmune To Acquire Spitfire Pharma For $5M, Add NASH Drug To Portfolio

    Altimmune (NASDAQ: ALT ) shares are trading higher after the company announced it will acquire Spitfire Pharma , which will add a non-alcoholic steatohepatitis (NASH) drug candidate to the company's portfolio. ...

  • MarketWatch

    Altimmune's stock soars after adding NASH candidate with purchase of Spitfire Pharma

    Shares of Altimmune Inc. soared 14% in premarket trading Tuesday, after the biopharmaceutical company announced a deal to buy Spitfire Pharma Inc., which is developing a treatment for non-alcoholic steatohepatitis, known as NASH. Altimmune will make an upfront payment of $5 million to Spitfire shareholders, who will also be eligible to receive an additional $8 million in regulatory and clinical milestones and up to $80 million in sales-based milestones. The deal is expected to close in July. Spitfire's NASH product candidate SP-1373 will be renamed ALT-801. "Compelling preclinical data generated by Spitfire suggests that ALT-801 could reverse obesity, a primary cause of NASH, thereby reducing excess liver fat, inflammation and fibrosis associated with the disease," said Altimmune Chief Executive Vipin Garg. Altimmune's stock has tumbled 21.1% over the past three months through Monday, while the iShares Nasdaq Biotechnology ETF has lost 4.3% and the S&P 500 has gained 3.4%.

  • GlobeNewswire

    Altimmune Signs Definitive Agreement to Acquire Spitfire Pharma, Inc. Adding NASH Drug Candidate to Portfolio

    Company to conduct conference call on Tuesday, July 9, 2019 at 8:30 a.m. GAITHERSBURG, Md., July 09, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. (ALT), a clinical-stage biopharmaceutical company, today announced that it has entered into an agreement to acquire Spitfire Pharma, Inc. (Spitfire) including its product candidate SP-1373 (to be renamed ALT-801), a potent GLP-1/Glucagon receptor co-agonist for the treatment of non-alcoholic steatohepatitis (NASH).

  • GlobeNewswire

    Altimmune Appoints Will Brown as Chief Financial Officer

    Altimmune, Inc. (ALT), a clinical-stage biopharmaceutical company, today announced it has appointed Will Brown as Chief Financial Officer. Mr. Brown has been serving as the Acting Chief Financial Officer since May 2018. “Will has proven to be a valuable member of our senior leadership team since he stepped into the CFO role over a year ago,” said Vipin K. Garg, Ph.D., President and Chief Executive Officer.

  • GlobeNewswire

    Altimmune Announces Successful Pre-IND Meeting with FDA

    Altimmune, Inc. (ALT), a clinical-stage biopharmaceutical company, today announced that it successfully completed a pre-IND (Investigational New Drug) meeting with the U.S. Food and Drug Administration (FDA) regarding its Phase 2 trial design and manufacturing plans for HepTcell. The FDA did not object to the planned study design and patient populations, as well as plans for manufacturing and product testing, and did not recommend any additional studies in preparation for an IND submission and initiation of Phase 2 trials. Altimmune intends to conduct a Phase 2 study in the United States and the pre-IND meeting was held to obtain feedback from the FDA on our intended development path.

  • GlobeNewswire

    Altimmune Announces Important Additions to its Patent Portfolio for HepTcell and ALT-702 Programs

    Altimmune, Inc. (ALT), a clinical-stage biotechnology company, today announced that it has received additional patent protection for its HepTcell and ALT-702 programs in the United States. “We are pleased to strengthen our intellectual property protection with the additional patents covering our development candidates, HepTcell and ALT-702,” said Vipin K. Garg, Ph.D., President and Chief Executive Officer. For HepTcell, the Company has been granted U.S. Patent No. 10,300,132 entitled “Vaccines Against Hepatitis B Virus.” The patent, which expires in 2035 accounting for 515 days of patent term adjustment, provides important additional IP protection for the HepTcell clinical development program, an immunotherapeutic being developed for patients chronically infected with the hepatitis B virus (“HBV”).

  • GlobeNewswire

    Altimmune Announces First Quarter 2019 Financial Results and Provides a Business Update

    GAITHERSBURG, Md., May 14, 2019 -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced financial results for the first quarter ended.

  • GlobeNewswire

    Altimmune to Announce First Quarter 2019 Financial Results on May 15

    GAITHERSBURG, Md., May 08, 2019 -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced that it will announce financial results for the.

  • GlobeNewswire

    Altimmune To Present NasoVAX Phase 2 Data at the World Vaccine Congress in Washington, D.C.

    Altimmune, Inc. (ALT), a clinical-stage immunotherapeutics company, today announced an oral presentation at the World Vaccine Congress being held in Washington D.C. on April 14-17, 2019. The presentation will take place on April 16, 2019 at the Renaissance Washington, DC Downtown Hotel at 12:55pm Eastern Time. Dr. Sybil Tasker, Chief Medical Officer of Altimmune, will present data from the Company’s Phase 2 study and the recently completed Phase 2 extension study for NasoVAX.

  • ACCESSWIRE

    Altimmune, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / April 2, 2019 / Altimmune, Inc. (NASDAQ: ALT ) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on April 2, 2019 at 8:30:00 AM Eastern ...

  • GlobeNewswire

    Altimmune Announces Financial Results for the Year Ended December 31, 2018 and Provides Corporate Update

    GAITHERSBURG, Md., April 01, 2019 -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced financial results for the year ended December.

  • GlobeNewswire

    Altimmune to Announce Year End 2018 Financial Results on April 2

    GAITHERSBURG, Md., March 21, 2019 -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced that it will announce financial results for the.

  • Altimmune News: ALT Stock Skyrockets on Positive Flu Vaccine Data
    InvestorPlace

    Altimmune News: ALT Stock Skyrockets on Positive Flu Vaccine Data

    Altimmune news concerning the results from a Phase 2 extension study of the company's NasoVAX has ALT stock heading higher today.Source: Shutterstock Altimmune (NASDAQ:ALT) says that it saw strong results from an extension to the study that has it checking in on patients one year after its completion. This includes 100% of patients that returned for the study extension still being seroprotected.The Altimmune news about its intranasal influenza vaccine candidate NasoVAX notes that patients in the extension were also saw a seroconversion rate that was unchanged from last year. It is also worth noting that these patients were from the highest dosage level of the study.InvestorPlace - Stock Market News, Stock Advice & Trading Tips"We are excited about the continued positive NasoVAX results and believe that if approved, NasoVAX has the potential to capture a significant portion of the global flu vaccine market," Vipin Garg, Ph.D., President and CEO of Altimmune, said in a statement. "Based on the continued positive data, we are seeking development and commercialization partnerships for our NasoVAX program. This will allow us to focus on our strategy of building a pipeline of multiple early to mid-stage assets." * Top 7 Service Sector Stocks That Will Pay You to Own Them The original study from Altimmune about using NasoVAX as an influenza vaccine had 13 people receiving the highest dosage of the vaccine. All 13 were invited to return for the extension, but only eight chose to do so.ALT stock was up 15% as of noon Tuesday and is up 11% since the start of the year. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Financial Stocks to Invest In Today * 7 Single-Digit P/E Stocks With Massive Upside * 5 Chip Stocks on the Rise As of this writing, William White did not hold a position in any of the aforementioned securities.Compare Brokers The post Altimmune News: ALT Stock Skyrockets on Positive Flu Vaccine Data appeared first on InvestorPlace.

  • GlobeNewswire

    Altimmune Announces Positive Results from NasoVAX Extension Study

    Altimmune, Inc. (ALT), a clinical-stage immunotherapeutics company, today announced additional positive data from a Phase 2 extension study of its NasoVAX intranasal influenza vaccine candidate. Data from this study demonstrated that 100% of the evaluated subjects remained seroprotected, and the seroconversion rate was unchanged more than one year after vaccination. Subjects from the highest dose group of the study were invited to return as part of a study extension to evaluate the duration of immunity 1-year post-vaccination.

  • GlobeNewswire

    Altimmune to Participate at 31st Annual ROTH Conference

    GAITHERSBURG, Md., March 14, 2019 -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, announced today that Vipin K. Garg, Ph.D., President and Chief.